Noradrenalina Kabi (Noradrenaline Tartrate)

• Noradrenalina Kabi is used in critical care to support cardiovascular function in conditions characterized by low blood pressure or impaired cardiac output.
• Hypotension: restores arterial pressure by inducing vasoconstriction, helping maintain organ perfusion in acute low‑blood‑pressure states, especially during anesthesia or trauma.
• Septic shock: counteracts vasodilatory shock by increasing systemic vascular resistance, thereby improving hemodynamic stability during severe infection, including refractory cases unresponsive to fluid resuscitation.
• Cardiac arrest: provides immediate alpha‑ and beta‑adrenergic stimulation to augment coronary and cerebral perfusion during resuscitation efforts, and supports myocardial oxygen delivery during advanced cardiac life support.

• Noradrenaline acts as a direct agonist at α1‑adrenergic receptors on vascular smooth muscle, causing potent vasoconstriction, and at β1‑adrenergic receptors in the heart, increasing contractility and heart rate. The combined α‑ and β‑stimulating effects raise systemic vascular resistance and cardiac output, thereby elevating arterial blood pressure in acute circulatory failure. These actions are rapid and dose‑dependent, allowing clinicians to titrate infusion rates to achieve target hemodynamic parameters.

Noradrenaline infusion may be associated with a range of adverse reactions, varying from common to serious.

Common Side Effects

• Tachycardia: increased heart rate due to β1 stimulation, may be transient.
• Hypertension: excessive rise in blood pressure from α1 vasoconstriction, requiring dose adjustment.
• Headache: vascular tension leading to cranial discomfort, often mild and self‑limiting.
• Peripheral ischemia: reduced blood flow to extremities causing coldness, pain, or discoloration.

Serious or Rare Side Effects

• Myocardial ischemia: reduced coronary perfusion that can cause chest pain, ECG changes, or infarction, especially in patients with pre‑existing coronary disease.
• Severe arrhythmias: life‑threatening rhythm disturbances such as ventricular tachycardia or fibrillation that may require immediate intervention.
• Tissue necrosis at infusion site: extravasation of the drug leading to local tissue damage, ulceration, or necrosis if not promptly managed.

When using Noradrenalina Kabi, clinicians should observe several precautions to minimize risks and ensure therapeutic effectiveness.

• Blood pressure monitoring: continuously assess arterial pressure to titrate infusion.
• Heart rate monitoring: watch for tachyarrhythmias and adjust dose accordingly.
• Dose titration: start with low infusion rates and increase gradually based on response.
• Caution in coronary disease: avoid excessive doses that may precipitate myocardial ischemia.
• Interaction with MAO inhibitors: avoid concurrent use due to risk of hypertensive crisis.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Noradrenaline can interact with several medications, altering its hemodynamic effects or increasing adverse event risk.

Major Interactions (Avoid)

• MAO inhibitors: may cause severe hypertension when combined.
• Tricyclic antidepressants: increase catecholamine levels, raising risk of hypertensive episodes.
• Beta‑blockers: blunt β1 effects, reducing desired cardiac stimulation.
• Other vasopressors: additive vasoconstriction can lead to excessive blood pressure.
• Clonidine: opposing actions may cause unpredictable blood pressure changes.

Moderate Interactions (Monitor Closely)

• Diuretics: may enhance hypotensive response after drug withdrawal.
• Calcium channel blockers: can modify vascular tone and affect blood pressure control.
• Anesthetic agents: may potentiate cardiovascular depression when noradrenaline is tapered.
• ACE inhibitors: may influence renal perfusion during therapy.
• Digitalis: combined effect on heart rate requires careful monitoring.